

MAY 16 2002

K020516

13 Appendix G: 510(k) Summary

510(k) Summary

Submitter's Information: Christian E. Hunt
Care Rehab[®]
1124 Dominion Ct Phone: 1-703-448-9644
McLean, VA 22102 FAX: 1-703-356-2182

Date of preparation: May 14, 2002

Proprietary Name: CARE IFC plus[™]

Common Name: Interferential Stimulator (LIH)

Classification Name: Stimulator Interferential (LIH); Unclassified

Device Classification: Unclassified

Predicate Device: HMP4000 Interferential Stimulator (K924961)

Description of Device: A portable Interferential device for pain control

Intended Use: Interferential treatment is used for symptomatic relief of chronic intractable pain and/or as an adjunctive treatment in the management of postsurgical and posttraumatic acute pain.

Technological Comparison: The CARE IFC plus[™] has technological characteristics that are substantially equivalent to those of the predicate device, as determined by bench testing.

Labeling Comparison: The labeling of the CARE IFC plus[™] is substantially equivalent to that of the predicate device.

Nonclinical Testing: Bench testing demonstrated that the output characteristics of CARE IFC plus[™] are substantially equivalent to that of the predicate device.

Clinical Testing: Not applicable.

Conclusions from Testing: The CARE IFC plus[™] is substantially equivalent in electrical output to the predicate device and any differences between the devices do not pose new questions of safety and effectiveness.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

MAY 16 2002

Mr. Christian E. Hunt
Care Rehab
1124 Dominion Ct.
McLean, VA 22102

Re: K020516
Trade/Device Name: CARE IFC plus
Regulatory Class: Unclassified
Product Code: LIH
Dated: February 14, 2002
Received: February 15, 2002

Dear Mr. Hunt:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 - Mr. Christian Hunt

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



for Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and

Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

4 Indications for Use

510(k) Number: _____

Device Name: CARE IFC plus™

Indications for Use:

Symptomatic relief of chronic intractable pain, post-traumatic and post-surgical pain

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE AS NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Miriam C. Provost
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

510(k) Number K020516